Nappi G, Martignoni E, Horowski R, Pacchetti C, Rainer E, Bruggi P, Runge I
Department of Neurology, Parkinson's Disease Centre, IRCCS C. Mondino, University of Pavia, Italy.
Acta Neurol Scand. 1991 Jun;83(6):407-10. doi: 10.1111/j.1600-0404.1991.tb03973.x.
We treated 20 early Parkinson's disease subjects with the dopamine agonist lisuride in combination with the MAO-B inhibitor selegiline (L-deprenyl). We started with lisuride alone for one month, then we added selegiline versus placebo to lisuride in double-blind conditions for 3 months; finally all patients received lisuride and selegiline for another 3 months. Lisuride alone (1.43 +/- 0.10 mg) significantly improved PD. When selegiline (10 mg/day) was added in the double-blind phase the mean lisuride dosage could be reduced by 22.8% without deterioration of the clinical effects, and the same occurred in the former placebo group when selegiline was added. The combination of both drugs was well tolerated. These data are of interest for the interpretation of the effects of selegiline.
我们用多巴胺激动剂利苏力特联合单胺氧化酶-B抑制剂司来吉兰（L-丙炔苯丙胺）治疗了20例早期帕金森病患者。我们先单独使用利苏力特治疗1个月，然后在双盲条件下将司来吉兰与安慰剂加至利苏力特中治疗3个月；最后所有患者再接受利苏力特和司来吉兰联合治疗3个月。单独使用利苏力特（1.43±0.10毫克）可显著改善帕金森病。在双盲阶段加入司来吉兰（每日10毫克）后，利苏力特的平均剂量可降低22.8%，而临床疗效并未恶化，在前安慰剂组加入司来吉兰后也出现了同样情况。两种药物联合使用耐受性良好。这些数据对于解释司来吉兰的作用很有意义。
